The effect of inositol on the improvement of primary sclerosing cholangitis patients
Phase 3
Recruiting
- Conditions
- Primary Sclerosing Cholangitis.Obstruction of bile ductK83.1
- Registration Number
- IRCT20220417054557N2
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
cholestatic liver disease for at least 6 months
serum alkaline phosphatase levels 1.5 times the normal upper limit
Exclusion Criteria
co-existing liver diseases such as alcoholic liver disease and NAFLD, autoimmune hepatitis, chronic B or C hepatitis, PBC, hemochromatosis, Wilson's disease, congenital biliary disease, and cholangiocarcinoma
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie inositol's therapeutic effects in primary sclerosing cholangitis?
How does inositol compare to UDCA and obeticholic acid in PSC treatment efficacy and safety profiles?
Which biomarkers could predict inositol response in PSC patients with bile duct obstruction (K83.1)?
What adverse events are associated with inositol therapy in cholestatic liver diseases?
Are there synergistic effects when combining inositol with FXR agonists or other PSC investigational agents?